Tempus AI: No AI Interruption Detected
Update - Mar. 18, 2025
Tempus AI continues to slow to the lows below $50 now. The stock is tasty once the shake out is over.

Originally posted on Feb. 25
- Tempus AI, Inc. has declined 50% from highs, now trading near support despite robust above $50, despite good Q4 results and strong organic growth.
- The AI precision medicine company delivered 33% organic growth with Diagnostics revenue expanding due to higher test ASPs.
- Concerns over AI replacement have pressured the stock, yet TEM's proprietary data and hospital network provide defensible moats.
- At 6.5x 2026 sales and strong contract retention, TEM stock appears undervalued; I am ultra Bullish and see current weakness as a buying opportunity.
Tempus AI, Inc. (TEM) has seen the stock continue to slide over the last few months, leaving Tempus down 50% from the highs. The AI precision medicine company has seen the stock slip back to support in the $50 to $55 range despite ongoing strong results, including a solid Q4 earnings beat. My investment thesis is ultra Bullish on the stock now.
Read the full article on Seeking Alpha.
Disclosure: No position mentioned. Please read the disclaimer page for more details.
Comments